Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs TJX Companies Inc (TJX) Price & Performance

BridgeBio Pharma IncTrade
TJX Companies IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs TJX Companies Inc — how do they compare? BridgeBio Pharma Inc trades at $83.45 (market cap $16.36B), while TJX Companies Inc trades at $152.52 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 10.5× BridgeBio Pharma Inc's market cap, and TJX Companies Inc pays a 1.23% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOTJX
Market Cap
$16.36B$172.05B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$168.41
52-Week Low
$47.29$132.62
Enterprise Value
$18.14B$180.65B
Dividend Yield
1.23%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.

Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.

TJX Companies Inc

TJX trades at $152.64, down 3.88% in the last session, with a bearish technical signal but strong fundamentals including a 61.25% ROE and consistent earnings beats. Revenue grew to $56.36B in 2025, with net income margin expanding to 8.63%. The company maintains robust cash flow from operations at $6.12B and announced dividends of $0.48 per share for H1 and H2 2026.

Outlook remains positive with analyst consensus price target of $181.80 (19% upside), supported by 88% buy ratings. Risks include competitive discount retail pressures and macroeconomic sensitivity, but TJX's value proposition and growth trajectory offer investment opportunity pending Q2 2026 earnings on August 19, 2026.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About TJX Companies Inc

TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.

Read more on TJX